Clinical trials: SCHIZOPHRENIA 1 (Disorder)
SCHIZOPHRENIA 1 (Disorder), Simulation Based Learning
Simulation-Based Schizophrenia Training in Nursing Education
This study aims to examine the effect of a schizophrenia scenario-based simulation on nursing students' knowledge, empathy, and caregiving competence. The study uses a single-group pre-test/post-test (quasi-experimental) design.
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Simulation Based Learning, Nursing Students
- Trial name
- NCT07757750
- Testing
- Simulation
- Where
- Turkey (Türkiye)
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Medipol University
SCHIZOPHRENIA 1 (Disorder), Psychosocial Adaptation
The Effects of a Solution-Focused Approach on Psychosocial Adjustment and Treatment Compliance in Individuals Diagnosed With Schizophrenia
The aim of this study is to evaluate the effects of a solution-focused approach-based individual intervention on psychosocial adjustment and treatment adherence in individuals diagnosed with schizophrenia.
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Psychosocial Adaptation, Treatment Adherence
- Trial name
- NCT07144592
- Testing
- solution-oriented approach program
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Muş Alparslan University
Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis
A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017
This is a phase 1，randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects.
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06388551
- Testing
- LY03017
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia
A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of 14 days of treatment with PF-05180999 in healthy subjects.
- Trial name
- NCT01429740
- Testing
- PF-05180999
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Pfizer
Schizophrenia / Schizoaffective Disorder, SCHIZOPHRENIA 1 (Disorder)
Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 3
In Study 3, all tasks and models from Aim 1 will be evaluated in a large community sample of online participants recruited through Prolific.
- Conditions
- Schizophrenia / Schizoaffective Disorder, SCHIZOPHRENIA 1 (Disorder), Healthy Adult
- Trial name
- CNTRACS (NCT07900893)
- Testing
- Motion Perception Task, Sine Wave Speech Task, Volatility Task
- Where
- 2 sites in United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizophrenia, Cerebellar Ataxia
A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants
The purpose of this study is to determine the safety, tolerability and pharmacokinetics (PK) of single and multiple rising doses of TAK-831 in healthy participants.
- Trial name
- NCT02566759
- Testing
- TAK-831 Oral Suspension, TAK-831 Tablet
- Where
- United Kingdom
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Neurocrine Biosciences
Tobacco Use Cessation, Tobacco Use Disorder
Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1
Schizophrenic individuals are typically nicotine dependent smokers who find it difficult to quit smoking. The purpose of this study is to determine the effectiveness of bupropion SR (commonly known as Zyban) in combination with a…
- Conditions
- Tobacco Use Cessation, Tobacco Use Disorder, Schizophrenia
- Trial name
- NCT00124683
- Testing
- Bupropion, nicotine transdermal patch
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Cognitive Function 1, Social
Social Cognition Assessment in Young Adults
The primary objective of this study is to determine the efficacy and feasibility of a battery of neuropsychological measures evaluating social cognition and behavior in young adults diagnosed with schizophrenia, autism spectrum…
- Trial name
- NCT02922400
- Testing
- Social Cognition Assessment and Training
- Where
- United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- The University of Texas at Dallas
Healthy
A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999
The purpose of this study is to assess the bioavailability, safety, and tolerability of a modified-release formulation of PF-05180999 relative to an immediate-release formulation in healthy adult subjects.
- Trial name
- NCT01530529
- Testing
- PF-05180999
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
SCHIZOPHRENIA 1 (Disorder), Sensory Perceptual Characteristics
Precision HD-tACS for Enhancing Sensory Experience in Schizophrenia
To ensure unified sensory perception, the brain must link information from different senses across time and space. This unification of perception often referred to as a perceptual "binding constraint" is a prerequisite for any…
- Trial name
- TherACles (NCT07632261)
- Testing
- Transcranial neurostimulation
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hôpital le Vinatier
Healthy
Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects
This Phase 1 study is the first clinical trial in Japanese subjects. The study is designed to evaluate the single- and multiple-dose pharmacokinetics, safety and tolerability of PF-03463275 oral controlled release formulation in…
- Trial name
- NCT01159626
- Testing
- PF-03463275
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer
Schizophrenia
Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time.
A PET study using [11c]GSK931145 to characterise the exposure-occupancy relationship over time for GSK1018921.
- Trial name
- NCT00945503
- Testing
- GSK1018921
- Where
- Spain
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia
Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of APN1125 when administered as single doses to healthy adult subjects.
- Trial name
- NCT02331433
- Testing
- APN1125
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- CoMentis
Parenting, Psychosis
Understanding and Helping Families: Parents With Psychosis
The purpose of this trial is to explore parent-child interactions in parents with and without psychosis, and ascertain whether a brief (10 week) supported self-help parenting program offered to parents in their own homes can help…
- Conditions
- Parenting, Psychosis, Schizophrenia
- Trial name
- NCT02622048
- Testing
- Triple P Positive Parenting Programme
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Schizophrenia
Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242
This study involves evaluating the occupancy of ATI-9242 at steady state at three different dose levels on D2 receptors in the brain using [18F] Fallypride PET in up to three cohorts of subjects.
- Trial name
- NCT02824666
- Testing
- ATI-9242, [18F]Fallypride Imaging
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Braeburn Pharmaceuticals
Schizophrenia, Psychotic Disorders
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive deficits are already present at the first break of the illness, seem to remain stable during early phases and noticeably influence…
- Trial name
- PAFIP2_nc1Y (NCT02534363)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Schizophrenia
Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia
The purpose of this study is to characterize the safety and tolerability profile of ITI-214 when administered as multiple doses of oral solution at escalating dose levels.
- Trial name
- NCT01900522
- Testing
- ITI-214 Dose A, ITI-214 Dose B, ITI-214 Dose C
- Where
- 2 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Takeda
SCHIZOPHRENIA 1 (Disorder), Borderline Personality Disorder
Disorders of the Sense of Self and Physical Activity
Schizophrenia (SZ) patients with metabolic syndrome, patients with vestibular syndrome, and patients with borderline personality disorder, would benefit from physical activity (PA).
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Borderline Personality Disorder, Vestibular Syndromes
- Trial name
- sensdesoi (NCT06817980)
- Testing
- Physical activity
- Where
- France
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Schizophrenia
A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults
The purpose of the present trial is to obtain information on the absorption, distribution, metabolism, excretion and pharmacokinetics (PK) of 14C-SEP-380135 and its metabolites following a single oral dose.
- Trial name
- NCT07455084
- Testing
- 14C-SEP-380135
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
SCHIZOPHRENIA 1 (Disorder), Schizoaffective Disorder
Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1
In Study 1, investigators will test the ability of each of the seven paradigms to differentiate between schizophrenia (SZ)/schizoaffective disorder (SZA) and matched healthy control subjects (HC) and to predict individual…
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Schizoaffective Disorder, Healthy Adult Participants
- Trial name
- CNTRACS (NCT07853807)
- Testing
- Motion Perception Task, Sine Wave Speech Task, Volatility Task
- Where
- 5 sites in United States
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine